Diabetes care: First drug to delay onset of type 1 diabetes made available on NHS
In a landmark announcement, the NHS has introduced a beacon of hope for individuals susceptible to type 1 diabetes. Teplizumab, an innovative medication, is now able to delay the disease's onset for an average of three years, focusing on the autoimmune process impacting the pancreas. This breakthrough provides vital time for young patients, allowing them to manage their health more effectively before the disease fully manifests.
In a landmark announcement, the NHS has introduced a beacon of hope for individuals susceptible to type 1 diabetes. Teplizumab, an innovative medication, is now able to delay the disease's onset for an average of three years, focusing on the autoimmune process impacting the pancreas. This breakthrough provides vital time for young patients, allowing them to manage their health more effectively before the disease fully manifests.
